Lipella Pharmaceuticals Inc. has closed a registered direct offering priced at-the-market under Nasdaq rules, generating approximately $1.28 million in gross proceeds. The net proceeds from the offering will be allocated towards working capital and general corporate purposes.
Company Information
Company
Lipella Pharmaceuticals
Location
400 N Lexington Ave
Pittsburgh, Pennsylvania, United States
About
Lipella is a biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis, also called radiation cystitis, when hemorrhagic cystitis occurs after pelvic radiation, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. We are also applying our proprietary drug delivery to the oral mucosa for the treatment of oral lichen planus.
PittsburghBiotechnologyHealthcareHealth CareMedicalTherapeuticsPharmaceuticalBiopharma